

## ACO Name and Location

Lifespan Health Alliance, LLC  
167 Point Street  
Suite 2B  
Providence, Rhode Island 02903

## ACO Primary Contact

<i>Primary Contact Name</i>	<b>Daniel Moynihan, Executive Director</b>
<i>Primary Contact Phone Number</i>	<b>401-444-3649</b>
<i>Primary Contact Email Address</i>	<b>Dmoynihan1@lifespan.org</b>

## Organizational Information

### ACO participants:

<b>ACO Participants</b>	<b>ACO Participant in Joint Venture (Enter Y or N)</b>
David Steigman	Y
The Miriam Hospital	Y
Newport Hospital	Y
Rhode Island Hospital	Y
Medical Associates Of Ri, Inc.	Y
Lifespan Physician Group, Inc	Y
University Orthopedics Inc	Y
University Medicine Foundation, Inc.	Y
Richard J. Ruggieri, Md, Inc.	Y
Anchor Medical Associates	Y
Women's Internal Medicine Inc.	Y
Hope Hospice & Palliative Care Rhode Island	Y
University Internal Medicine Inc	Y

**ACO governing body:**

Member			Member's Voting Power	Membership Type	ACO Participant TIN Legal Business Name/DBA, if Applicable
Last Name	First Name	Title/Position			
Lampert	Steve	Chairman	.125	ACO Participant	Lifespan Physician Group
Beraha	Nathan	Vice Chairman	.125	ACO Participant	Anchor Medical Group
Harrop	Pamela	Member	.125	ACO Participant	Medical Associates of Rhode Island
Hollmann	Peter	Member	.125	ACO Participant	University Medicine
Marcoux	David	Member	.125	ACO Participant	University Internal Medicine
Van Bree	Margaret	Member	.125	ACO Participant	Rhode Island Hospital
Wakefield	Mary	Treasurer	.125	ACO Participant	Miriam Hospital Corp.
Sadwin	Lawrence	Member	.125	Medicare Beneficiary	N/A

**Key ACO clinical and administrative leadership:**

Daniel Moynihan	ACO Executive
Peter Hollmann	Medical Director
Thomas Igoe	Compliance Officer
Peter Hollmann, MD	Quality Assurance/Improvement Officer

**Associated committees and committee leadership:**

Committee Name	Committee Leader Name and Position
Clinical and Quality Management	Peter Hollmann, MD Chair
Compliance Committee	Angela Prew, Chair
Finance Committee	Nathan Beraha, MD Chair
Data Governance Committee	Steve Lampert, MD Chair

**Types of ACO participants, or combinations of participants, that formed the ACO:**

- Partnerships or joint venture arrangements between hospitals and ACO professionals
- Network of individual practices of ACO professionals
- ACO professionals in a group practice arrangement

**Shared Savings and Losses****Amount of Shared Savings/Losses**

- N/A

**Shared Savings Distribution**

- N/A

**Quality Performance Results****2016 Quality Performance Results:**

ACO#	Measure Name	Rate	ACO Mean
ACO-1	CAHPS: Getting Timely Care, Appointments, and Information	N/A	80.51
ACO-2	CAHPS: How Well Your Providers Communicate	N/A	93.01
ACO-3	CAHPS: Patients' Rating of Provider	N/A	92.25
ACO-4	CAHPS: Access to Specialists	N/A	83.49
ACO-5	CAHPS: Health Promotion and Education	N/A	60.32
ACO-6	CAHPS: Shared Decision Making	N/A	75.40
ACO-7	CAHPS: Health Status/Functional Status	N/A	72.30
ACO-34	CAHPS: Stewardship of Patient Resources	N/A	26.97

ACO-8	Risk Standardized, All Condition Readmission	N/A	14.70
ACO-35	Skilled Nursing Facility 30-day All-Cause Readmission measure (SNFRM)	N/A	18.17
ACO-36	All-Cause Unplanned Admissions for Patients with Diabetes	N/A	53.20
ACO-37	All-Cause Unplanned Admissions for Patients with Heart Failure	N/A	75.23
ACO-38	All-Cause Unplanned Admissions for Patients with Multiple Chronic Conditions	N/A	59.81
ACO-9	Ambulatory Sensitive Condition Admissions: Chronic Obstructive Pulmonary Disease or Asthma in Older Adults (AHRQ Prevention Quality Indicator (PQI) #5)	N/A	9.27
ACO-10	Ambulatory Sensitive Conditions Admissions: Heart Failure (AHRQ Prevention Quality Indicator (PQI) #8)	N/A	14.53
ACO-11	Percent of PCPs who Successfully Meet Meaningful Use Requirements	N/A	82.72
ACO-39	Documentation of Current Medications in the Medical Record	N/A	87.54
ACO-13	Falls: Screening for Future Fall Risk	N/A	64.04
ACO-14	Preventive Care and Screening: Influenza Immunization	N/A	68.32
ACO-15	Pneumonia Vaccination Status for Older Adults	N/A	69.21
ACO-16	Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up	N/A	74.45
ACO-17	Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention	N/A	90.98
ACO-18	Preventive Care and Screening: Screening for Clinical Depression and Follow-up Plan	N/A	53.63
ACO-19	Colorectal Cancer Screening	N/A	61.52
ACO-20	Breast Cancer Screening	N/A	67.61
ACO-21	Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented	N/A	76.79
ACO-42	Statin therapy for the Prevention and Treatment of Cardiovascular Disease	N/A	77.72
ACO-27	Diabetes Mellitus: Hemoglobin A1c Poor Control	N/A	18.24
ACO-	Diabetes: Eye Exam	N/A	44.94

41			
ACO-28	Hypertension (HTN): Controlling High Blood Pressure	N/A	70.69
ACO-30	Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic	N/A	85.05
ACO-31	Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)	N/A	88.67
ACO-33	Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy - for patients with CAD and Diabetes or Left Ventricular Systolic Dysfunction (LVEF<40%)	N/A	79.67

Please note, the ACO-40 Depression Remission at 12 months quality measure is not included in public reporting due to low samples.

### Payment Rule Waivers

- No, our ACO does not use the SNF 3-Day Rule Waiver.